Vasomotor symptoms are associated with a lower bone mineral density

Menopause

Volumn 16, Issue 2, 2009, Pages 231-238

  Gast, Gerrie Cor M ^a,b   Grobbee, Diederick E ^a   Pop, Victor J M ^c   Keyzer, Jules J ^d   Gent, Colette J M Wijnands Van ^d   Samsioe, Göran N ^b   Nilsson, Peter M ^b   Van Der Schouw, Yvonne T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c TILBURG UNIVERSITY   (Netherlands)

^d Research Unit of the Diagnostic Center Eindhoven   (Netherlands)

Author keywords

Bone mineral density; Estrogen sensitive end organs; Hot flushes; Night sweating; Vasomotor symptoms

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDUCATIONAL STATUS; FEMALE; FLUSHING; GROUPS BY AGE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSE; MORBIDITY; NIGHT SWEAT; SMOKING HABIT; STRUCTURED QUESTIONNAIRE; VASOMOTOR DISORDER;

BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; QUALITY OF LIFE; SWEATING; VASOMOTOR SYSTEM;

EID: 67649329755     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318185e25b     Document Type: Article

References (55)

1. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J 2005;26: 1358-1361.
2. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
3. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
5. Hulley S, Grady D, Bush T, et al Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Leal M, Diaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol 2000;95:804-809.
8. Naessen T, Persson I, Ljunghall S, Bergstrom R. Women with climacteric symptoms: a target group for prevention of rapid bone loss and osteoporosis. Osteoporos Int 1992;2:225-231.
9. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339: 733-738.
10. Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR. Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1998;13:1167-1174.
11. Hagemans ML, van der Schouw YT, de Kleijn MJ, et al. Indicators for the total duration of premenopausal endogenous estrogen exposure in relation to BMD. Hum Reprod 2004;19:2163-2169.
12. Smeets-Goevaers CG, Lesusink GL, Papapoulos SE, et al. The prevalence of low bone mineral density in Dutch perimenopausal women: the Eindhoven Perimenopausal Osteoporosis Study. Osteoporos Int 1998;8:404-409.
13. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008;93:861-868.
14. Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause 2007;14:567-571.
15. Whiteman MK, Staropoli CA, Benedict JC, Borgeest C, Flaws JA. Risk factors for hot flashes in midlife women. J Womens Health (Larchmt) 2003;12:459-472.
16. Huang AJ, Grady D, Jacoby VL, Blackwell TL, Bauer DC, Sawaya GF. Persistent hot flushes in older postmenopausal women. Arch Intern Med 2008;168:840-846.
17. Boker LK, van Noord PA, van der Schouw YT, et al. Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition. Eur J Epidemiol 2001;17:1047-1053.
18. Thurston RC, Sowers MR, Sutton-Tyrrell K, et al. Abdominal adiposity and hot flashes among midlife women. Menopause 2008;15: 429-434.
19. Freeman EW, Sammel MD, Grisso JA, Battistini M, Garcia-Espagna B, Hollander L. Hot flashes in the late reproductive years: risk factors for Africa American and Caucasian women. J Womens Health Gend Based Med 2001;10:67-76.
20. Kaufert PA, Gilbert P, Hassard T. Researching the symptoms of menopause: an exercise in methodology. Maturitas 1988;10:117-131.
21. Carpenter JS. State of the science: hot flashes and cancer. Part 1: definition, scope, impact, physiology, and measurement. Oncol Nurs Forum 2005;32:959-968.
22. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-780.
23. Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. Duration of hormonal replacement therapy in general practice; a follow-up study. Maturitas 1998;29:125-131.
24. Campagnoli C, Morra G, Belforte P, Belforte L, Prelato TL. Climacteric symptoms according to body weight in women of different socio-economic groups. Maturitas 1981;3:279-287.
25. Erlik Y, Meldrum DR, Judd HL. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 1982;59:403-407.
26. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006;96:1226-1235.
27. Thurston RC, Sowers MR, Chang Y, et al. Adiposity and reporting of vasomotor symptoms among midlife women: the Study of Women's Health Across the Nation. Am J Epidemiol 2008;167:78-85.
28. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003; 101:264-272.
29. Freedman RR. Hot flash trends and mechanisms. Menopause 2002;9: 151-152.
30. Zachow RJ, Magoffin DA. Direct intraovarian effects of leptin: impairment of the synergistic action of insulin-like growth factor-I on follicle-stimulating hormone-dependent estradiol-17β production by rat ovarian granulosa cells. Endocrinology 1997;138:847-850.
31. Luheshi GN, Gardner JD, Rushforth DA, Loudon AS, Rothwell NJ. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci U S A 1999;96:7047-7052.
32. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000;15: 1965-1973.
33. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738.
34. Elders PJ, Netelenbos JC, Lips P, van Ginkel FC, van der Stelt PF. Accelerated vertebral bone loss in relation to the menopause: a crosssectional study on lumbar bone density in 286 women of 46 to 55 years of age. Bone Miner 1988;5:11-19.
35. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115.
36. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999; 181:66-70.
37. Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertil Steril 2002;77:487-490.
38. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70:332-337.
39. Bruck K, Hinckel P. Thermoregulatory noradrenergic and serotonergic pathways to hypothalamic units. J Physiol 1980;304:193-202.
40. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23:117-125.
41. Etgen AM, Ansonoff MA, Quesada A. Mechanisms of ovarian steroid regulation of norepinephrine receptor-mediated signal transduction in the hypothalamus: implications for female reproductive physiology. Horm Behav 2001;40:169-177.
42. Freedman RR. Menopausal hot flashes. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. 3rd ed. Burlington, MA: Academinc Press Elsevier Inc, 2007:187-198.
43. Hutton JD, Jacobs HS, Murray MA, James VH. Relation between plasma oestrone and oestradiol and climacteric symptoms. Lancet 1978;1:678-681.
44. Casper RF, Yen SS, Wilkes MM. Menopausal flushes: a neuroendocrine link with pulsatile leuteinizing hormone secretion. Science 1979;205: 823-825.
45. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985;22:293-312.
46. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
47. Martin-Escudero JC, Perez-Castrillon JL, Blanco FS, Rzua-Mouronte D, Bellido CJ, Martin JM. Relation between bone mass and catecholamines in the general population. Horm Res 2007;68:63-67.
48. Kondo H, Nifuji A, Takeda S, et al. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem 2005;280:30192-30200.
49. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 2002;58:77-84.
50. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923-928.
51. Gast GC, Grobbee DE, Pop VJ, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008;51: 1492-1498.
52. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008;87:1080S-1086S.
53. von Muhlen DG, Soroko S, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms are not associated with reduced bone mass in postmenopausal women: the Rancho Bernardo Study. J Womens Health Gend Based Med 2000;9:505-511.
54. Huang A, Grady D, Blackwell T, Bauer D. Hot flushes, bone mineral density, and fractures in older postmenopausal women. Obstet Gynecol 2007;109:841-847.
55. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.